Inlyta (generic name: axitinib) is prescribed as a first-line treatment for adult patients diagnosed with an advanced stage kidney cancer known as renal cell carcinoma (RCC). It is used as monotherapy or in conjunction with either pembrolizumab or avelumab.
Its primary mechanism of action is thought to inhibit angiogenesis (the formation of new blood vessels by tumors).
Reviews
There are no reviews yet.